Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure

NCT04642638 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT04642638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04642638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Randomized, Blinded, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of INO-4800, a Prophylactic Vaccine Against COVID-19 Disease, Administered Intradermally Followed by Electroporation in Adults at High Risk of SARS-CoV-2 Exposure
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 2/3
Overall status
Terminated
Start date
November 30, 2020
Completion date
September 13, 2022
Enrollment
1,307 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infection, covid-19 disease, severe acute respiratory syndrome coronavirus 2 (sars-cov-2)